Literature DB >> 11426579

Ultrastructural and immunohistochemical analysis of cholangiocarcinoma in immunized Syrian golden hamsters infected with Opisthorchis viverrini and administered with dimethylnitrosamine.

S Tesana1, Y Takahashi, P Sithithaworn, K Ando, T Sakakura, W Yutanawiboonchai, C Pairojkul, W Ruangjirachuporn.   

Abstract

Utilizing the experimental model in Syrian golden hamsters, we explored the role of immunization in carcinogenesis. The animals, which were infected with liver flukes (Opisthorchis viverrini), and administered a subcarcinogenic dose of dimethylnitrosamine, developed cancer. Pre-immunizing with a crude somatic antigen did not reduce cancer development, but accelerated carcinogenesis. Histopathological analysis of the cancer tissues was done once at week 30 and again at week 39 using H and E staining, immunostaining for the p53 tumor suppressor phosphoprotein, and electron microscopy. Thirty weeks after immunization, the immunized hamsters developed tubular adenocarcinoma at a higher rate (71.43%) than the non-immunized group (20.00%). This rate (20.00%) increased to 63.64% by week 39. The small foci cancer in the non-immunized group decreased in frequency from 80.00% (at week 30) to 36.36% (by week 39), suggesting the small foci cancer progressed to tubular adenocarcinoma during the 9-week interval. Most of the observed tubular adenocarcinoma was well differentiated. Nearly all hamsters that tested positive for cancer also tested positive for p53 immunostaining in the epithelia of the small bile ducts. The positive reaction for p53-immunostaining was localized in the rough endoplasmic reticulum, Golgi apparatus and perinuclear membranes. The electron micrographs of these positive p53-immunostained cells showed characteristics of early cancer. The detection of p53 in early cancer development makes it a candidate as a tumor marker.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11426579     DOI: 10.1016/s1383-5769(00)00052-0

Source DB:  PubMed          Journal:  Parasitol Int        ISSN: 1383-5769            Impact factor:   2.230


  7 in total

Review 1.  Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.

Authors:  Boris Blechacz; Gregory J Gores
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

2.  Molecular mechanisms of cholangiocarcinoma.

Authors:  Giammarco Fava
Journal:  World J Gastrointest Pathophysiol       Date:  2010-04-15

3.  Overexpression of microRNA-21 regulating PDCD4 during tumorigenesis of liver fluke-associated cholangiocarcinoma contributes to tumor growth and metastasis.

Authors:  P Chusorn; N Namwat; W Loilome; A Techasen; C Pairojkul; N Khuntikeo; A Dechakhamphu; C Talabnin; W Chan-On; C K Ong; B T Teh; P Yongvanit
Journal:  Tumour Biol       Date:  2013-02-17

4.  Establishment of a novel orthotopic xenograft model of human gallbladder carcinoma.

Authors:  Jan-Hendrik Egberts; Bodo Schniewind; Clemens Schafmayer; Marie-Luise Kruse; Bence Sipos; Fred Fändrich; Holger Kalthoff; Jürgen Tepel
Journal:  Clin Exp Metastasis       Date:  2007-04-04       Impact factor: 5.150

5.  Effect of Opisthorchis felineus infection and dimethylnitrosamine administration on the induction of cholangiocarcinoma in Syrian hamsters.

Authors:  Galina A Maksimova; Maria Y Pakharukova; Elena V Kashina; Natalya A Zhukova; Anna V Kovner; Maria N Lvova; Alexey V Katokhin; Tatyana G Tolstikova; Banchob Sripa; Viatcheslav A Mordvinov
Journal:  Parasitol Int       Date:  2015-10-09       Impact factor: 2.230

Review 6.  The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer.

Authors:  Abigail Zabron; Robert J Edwards; Shahid A Khan
Journal:  Dis Model Mech       Date:  2013-03       Impact factor: 5.758

Review 7.  Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers.

Authors:  Inga Hochnadel; Uta Kossatz-Boehlert; Nils Jedicke; Henrike Lenzen; Michael P Manns; Tetyana Yevsa
Journal:  Hum Vaccin Immunother       Date:  2017-11-07       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.